The case for & against
Bull & Bear analysis
Bearish
Curis, Inc. (NASDAQ: CRIS) is a biopharmaceutical company at the forefront of developing innovative cancer therapies, particularly focusing on hematological malignancies. The company leverages proprietary agents such as emavucirtib, primarily aimed at treating chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL). With recent advancements in clinical trials, Curis is positioned within a high-growth oncology market that emphasizes combination therapies, taking advantage of ongoing shifts in treatment paradigms; thus, the firm focuses on unmet medical needs in oncology.
Bull says
- ↑TAKE-AIM CLL study initiated with patient dosing expected mid-2026.
- ↑Proactive FDA collaboration aims to expedite U.S. and EU approvals.
- ↑Analyst price target bumped to $400 on clinical efficacy optimism.
- ↑R&D expenses cut from $8.5M to $6.4M YoY, boosting financial runway.
- ↑Dual-pathway emavucirtib approach may drive MRD-negative remissions in CLL.
- ↑Dividend yield of 0.78% and book-to-price ratio of 2.34 appeal to value investors.
Bear says
- ↓Q1 net loss of $24.2M ($1.25/sh) strains cash runway.
- ↓Negative earnings yield and weak profitability metrics hamper returns.
- ↓Pipeline success dependent on trial outcomes amid enrollment hurdles.
- ↓Extremely high short interest underscores investor skepticism.
- ↓Regulatory uncertainties may delay FDA and EU approval timelines.
- ↓Negative momentum and limited scale may restrict near-term upside.
Earnings Call · Q4 2025 · Mgmt. Guidance
Updated 04-21-2026neutral
Transcript signals
Bull points
- CURE supported net income of $19.4 million, or $1.23 per share, for the fourth quarter of 2025, as compared to a net loss of $9.6 million, or $1.25 per share, for the same period in 2024.
- The net income in the fourth quarter of 2025 is due to a $27.2 million one-time non-cash gain attributable to our sale of AeroVeg to Overland.
- Sears' cash and cash equivalents as of December 31, 2025, together with initial gross proceeds of $20.2 million received in January 2026, and expected gross proceeds of up to an additional $20.2 million from the exercise of the January 2026 pipe financing Series B warrants upon the public announcement of dosing of the fifth CLL patient in our Take Aim CLL study expected later this year, should enable our planned operations into the second half of 2027.
Bear points
- Research and development expenses were $28.3 million for the year ended December 31, 2025, as compared to $38.6 million for the same period in 2024.
- Research and development expenses were $28.3 million for the year ended December 31, 2025, as compared to $38.6 million for the same period in 2024.
- We'll have no meaningful revenue.
Read full transcript analysis ›